Abstract | OBJECTIVE: METHODS: RESULTS: A total of 183 women (56.1%) underwent primary cytoreductive surgery and 143 women (43.9%) received neoadjuvant chemotherapy. Women who received neoadjuvant chemotherapy were more likely to have no residual disease than those who underwent primary cytoreductive surgery (51.4% vs 41.5%; P = 0.030) but experienced inferior 10-year overall survival (9.1% vs 19.3%; P < 0.001). Among those who had primary cytoreductive surgery, those with no residual disease had superior 10-year overall survival than those who had any evidence of residual disease (36.0% vs 7.2%; P < 0.001). CONCLUSION:
|
Authors | Soyoun Rachel Kim, Joanne Kotsopoulos, Ping Sun, Marcus Q Bernardini, Stephane Laframboise, Sarah E Ferguson, Barry Rosen, Steven A Narod, Taymaa May |
Journal | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
(Int J Gynaecol Obstet)
Vol. 153
Issue 3
Pg. 417-423
(Jun 2021)
ISSN: 1879-3479 [Electronic] United States |
PMID | 33326624
(Publication Type: Journal Article)
|
Copyright | © 2020 International Federation of Gynecology and Obstetrics. |
Topics |
- Adult
- Aged
- Carcinoma, Ovarian Epithelial
(mortality, pathology, therapy)
- Chemotherapy, Adjuvant
- Cohort Studies
- Cytoreduction Surgical Procedures
- Female
- Humans
- Middle Aged
- Neoadjuvant Therapy
- Ovarian Neoplasms
(mortality, pathology, therapy)
- Retrospective Studies
|